CDEK
← All drugs Report issue

ligelizumab

mAbexperimental

Ligelizumab is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria. It is an anti-IgE that binds to IGHE an acts as an immunomodulator. It is delivered as a subcutaneous biologic injection. — Wikipedia

Clinical trial activity

20 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
17
Phase 3
7
Phase 4
0

Earliest trial started Mar 1, 2011 (NCT01596712)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Multi-specific
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ligelizumab
  • ligelizumab
  • ligelizumab
  • ligelizumab
  • qge031
  • qge031
  • qge-031

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05678959Phase 3Apr 27, 2023Novartis
NCT04984876Phase 3Dec 10, 2021Novartis
NCT05024058Phase 3Dec 9, 2021Novartis
NCT04513548Phase 1Aug 5, 2020Novartis
NCT04210843Phase 3Apr 30, 2020Novartis
NCT03907878Phase 3Apr 13, 2019Novartis
NCT03580369Phase 3Sep 10, 2018Novartis
NCT03580356Phase 3Sep 10, 2018Novartis
NCT03437278Phase 2May 1, 2018Novartis
NCT02649218Phase 2Jan 1, 2016Novartis
NCT02336425Phase 2Sep 1, 2015Novartis
NCT02477332Phase 2Jul 15, 2015Novartis
NCT02075008Phase 2Mar 27, 2014Novartis
NCT01688882Phase 2Jan 1, 2013Novartis
NCT01716754Phase 2Dec 1, 2012Novartis
NCT01703312Phase 1/Phase 2 (Phase 2)Nov 1, 2012Novartis
NCT01552629Phase 2Jan 5, 2012Novartis
NCT01451450Phase 2Oct 10, 2011Novartis
NCT01596712Phase 1Mar 1, 2011Novartis
NCT04903613N/A—Novartis
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
NovartisFor profit202042011
1 organizations
Page 1 / 1